Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice

December 3, 2019

Koorneef et al. • 2018 • Endocrinology. 2018, 159(12):3925–3936

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2019-12-03 00:00:002019-12-03 00:00:00Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

December 2, 2019

Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2019-12-02 00:00:002019-12-02 00:00:00Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.

September 19, 2018

Kroon et al. • 2017 • Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.

A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

September 19, 2018

Mammi et al. • 2016 • Int J Obes (Lond). 2016;40(6):964-72.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.

September 19, 2018

van den Heuvel et al. • 2016 • Br J Pharmacol. 2016;173(11):1793-804.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.

Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

September 19, 2018

Teich et al. • 2016 • Am J Physiol Endocrinol Metab. 2016;311(1):E56-68.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

September 19, 2018

Beaudry et al. • 2014 • PLoS One. 2014;9(3):e91248.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.

September 19, 2018

Hunt et al. • 2012 • Bioorg Med Chem Lett. 2012;22(24):7376-80.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.

Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.

September 19, 2018

Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.

Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.

September 19, 2018

Belanoff et al. • 2011 • Eur J Pharmacol. 2011;655(1-3):117-20.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Page 2 of 3123

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top